The U.S. District Court for the District of Rhode Island issues concerning ruling on drug patent settlements (Loestrin)

On September 4, 2014, Judge William Smith of the U.S. District Court for the District of Rhode Island issued a concerning ruling on drug patent settlements. In In re Loestrin 24 FE Antitrust Litigation, 2014 WL 4368924 (D.R.I., Sept. 4, 2014), Judge Smith misapplied the Supreme Court’s landmark decision in Federal Trade Commission (FTC) v. Actavis, 133 S. Ct. 2223 (2013), granting a motion to dismiss plaintiffs’ challenge to a settlement that had allegedly delayed generic entry. Facts The case involved Warner Chilcott’s Loestrin 24, a widely-used oral contraceptive. Direct purchasers (companies that purchased the drug directly from Warner Chilcott) and end payors (employee welfare benefit programs and three individuals) claimed that Warner Chilcott paid generics Watson (now known as

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Rutgers University (New Jersey)

Quotation

Michael A. Carrier, The U.S. District Court for the District of Rhode Island issues concerning ruling on drug patent settlements (Loestrin), 4 September 2014, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 69705

Visites 3228

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues